HOOKIPA Pharma (HOOK) Stock Forecast, Price Target & Predictions
HOOK Stock Forecast
HOOKIPA Pharma stock forecast is as follows: an average price target of $3.00 (represents a -39.88% downside from HOOK’s last price of $4.99) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
HOOK Price Target
The average price target for HOOKIPA Pharma (HOOK) is $3.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential -39.88% downside from HOOK's last price of $4.99.
HOOK Analyst Ratings
According to 4 Wall Street analysts, HOOKIPA Pharma's rating consensus is 'Buy'. The analyst rating breakdown for HOOK stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
HOOKIPA Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | - | Leerink Partners | $3.00 | $1.59 | 88.68% | -39.88% |
The latest HOOKIPA Pharma stock forecast, released on Aug 11, 2022 by Leerink Partners company, set a price target of $3.00, which represents a 88.68% increase from the stock price at the time of the forecast ($1.59), and a -39.88% decrease from HOOK last price ($4.99).
HOOKIPA Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $4.99 | $4.99 | $4.99 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of HOOKIPA Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HOOKIPA Pharma's last price of $4.99. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 21, 2024 | RBC Capital | Buy | Buy | Hold |
| May 21, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Nov 15, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Aug 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
HOOKIPA Pharma's last stock rating was published by JMP Securities on Aug 09, 2024. The company gave HOOK a "Outperform" rating, the same as its previous rate.
HOOKIPA Pharma Financial Forecast
HOOKIPA Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.41M | - | - | $3.18M | $7.83M | $2.23M | $2.75M | $1.45M | $-10.71M | $3.87M | $5.38M | $5.30M | $5.16M | $4.04M | $6.68M | $3.70M | $3.62M | $2.04M | $4.05M | $2.23M |
| Avg Forecast | $2.00M | $2.00M | $2.00M | $2.00M | $6.25M | $6.25M | $7.10M | $5.22M | $4.55M | $4.25M | $4.87M | $4.39M | $7.07M | $2.91M | $3.36M | $14.53M | $3.80M | $5.72M | $5.12M | $3.97M | $4.26M | $4.61M | $3.49M | $4.24M | $2.88M | $3.06M | $2.08M | $2.00M |
| High Forecast | $3.33M | $3.33M | $3.33M | $3.33M | $10.42M | $9.13M | $11.83M | $8.69M | $4.93M | $7.09M | $8.12M | $7.32M | $11.78M | $4.85M | $5.31M | $23.00M | $6.02M | $9.05M | $8.11M | $6.28M | $6.74M | $7.30M | $5.52M | $6.71M | $4.56M | $4.84M | $3.29M | $3.16M |
| Low Forecast | $634.92K | $634.92K | $634.92K | $634.92K | $1.98M | $3.37M | $2.25M | $1.66M | $4.17M | $1.35M | $1.55M | $1.39M | $2.24M | $923.17K | $1.37M | $5.93M | $1.55M | $2.33M | $2.09M | $1.62M | $1.74M | $1.88M | $1.42M | $1.73M | $1.18M | $1.25M | $848.46K | $816.48K |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.63% | - | - | 0.72% | 1.11% | 0.77% | 0.82% | 0.10% | -2.82% | 0.68% | 1.05% | 1.34% | 1.21% | 0.88% | 1.92% | 0.87% | 1.25% | 0.67% | 1.95% | 1.12% |
HOOKIPA Pharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $5.22M, with a low forecast of $1.66M, and a high forecast of $8.69M. HOOK's average Quarter revenue forecast represents a -29.58% decrease compared to the company's last Quarter revenue of $7.41M (Dec 23).
HOOKIPA Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-16.85M | $-22.67M | $-21.47M | $-22.66M | $-13.59M | $-17.41M | $-15.26M | $-16.65M | $-22.80M | $-18.71M | $-15.72M | $-15.92M | $-9.65M | $-12.76M | $-6.45M | $-10.29M | $-10.85M | $-10.38M | $-10.93M | $-8.55M |
| Avg Forecast | $-2.00M | $-2.00M | $-2.00M | $-2.00M | $-6.25M | $-6.25M | $-7.10M | $-5.22M | $-4.55M | $-4.25M | $-4.87M | $-4.39M | $-7.07M | $-20.60M | $-3.36M | $-13.12M | $-3.80M | $-5.72M | $-5.12M | $-15.92M | $-4.26M | $-4.61M | $-3.49M | $-10.04M | $-2.88M | $-3.06M | $-2.08M | $-32.48M |
| High Forecast | $-634.92K | $-634.92K | $-634.92K | $-634.92K | $-1.98M | $-3.37M | $-2.25M | $-1.66M | $-4.17M | $-1.35M | $-1.55M | $-1.39M | $-2.24M | $-16.48M | $-1.37M | $-10.49M | $-1.55M | $-2.33M | $-2.09M | $-12.73M | $-1.74M | $-1.88M | $-1.42M | $-8.04M | $-1.18M | $-1.25M | $-848.46K | $-25.99M |
| Low Forecast | $-3.33M | $-3.33M | $-3.33M | $-3.33M | $-10.42M | $-9.13M | $-11.83M | $-8.69M | $-4.93M | $-7.09M | $-8.12M | $-7.32M | $-11.78M | $-24.73M | $-5.31M | $-15.74M | $-6.02M | $-9.05M | $-8.11M | $-19.10M | $-6.74M | $-7.30M | $-5.52M | $-12.05M | $-4.56M | $-4.84M | $-3.29M | $-38.98M |
| Surprise % | - | - | - | - | - | - | - | - | 3.70% | 5.33% | 4.41% | 5.16% | 1.92% | 0.85% | 4.55% | 1.27% | 5.99% | 3.27% | 3.07% | 1.00% | 2.26% | 2.76% | 1.85% | 1.02% | 3.76% | 3.39% | 5.26% | 0.26% |
undefined analysts predict HOOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HOOKIPA Pharma's previous annual EBITDA (undefined) of $NaN.
HOOKIPA Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-24.82M | $-19.07M | $-18.02M | $-19.89M | $-12.54M | $-15.57M | $-16.36M | $-15.79M | $-21.23M | $-20.04M | $-17.15M | $-17.24M | $-12.47M | $-13.59M | $-7.09M | $-10.93M | $-10.24M | $-11.38M | $-12.08M | $-9.33M |
| Avg Forecast | $-25.08M | $-25.08M | $-23.82M | $-22.57M | $-17.74M | $-16.05M | $-15.70M | $-12.85M | $-35.20M | $-26.33M | $-26.12M | $-28.34M | $-25.97M | $-22.06M | $-45.14M | $-14.16M | $-71.29M | $-68.55M | $-65.20M | $-17.24M | $-70.43M | $-52.45M | $-57.68M | $-10.67M | $-58.31M | $-79.31M | $-63.95M | $-35.44M |
| High Forecast | $-2.83M | $-2.83M | $-2.68M | $-2.54M | $-2.00M | $-12.92M | $-1.77M | $-1.45M | $-25.34M | $-2.97M | $-2.94M | $-3.19M | $-2.93M | $-17.65M | $-10.41M | $-11.33M | $-16.45M | $-15.81M | $-15.04M | $-13.79M | $-16.25M | $-12.10M | $-13.31M | $-8.53M | $-13.45M | $-18.30M | $-14.75M | $-28.36M |
| Low Forecast | $-46.81M | $-46.81M | $-44.47M | $-42.13M | $-33.12M | $-19.18M | $-29.32M | $-23.99M | $-45.06M | $-49.15M | $-48.76M | $-52.90M | $-48.48M | $-26.48M | $-79.32M | $-16.99M | $-125.27M | $-120.44M | $-114.57M | $-20.69M | $-123.75M | $-92.17M | $-101.35M | $-12.80M | $-102.45M | $-139.35M | $-112.36M | $-42.53M |
| Surprise % | - | - | - | - | - | - | - | - | 0.71% | 0.72% | 0.69% | 0.70% | 0.48% | 0.71% | 0.36% | 1.12% | 0.30% | 0.29% | 0.26% | 1.00% | 0.18% | 0.26% | 0.12% | 1.02% | 0.18% | 0.14% | 0.19% | 0.26% |
HOOKIPA Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HOOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
HOOKIPA Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $3.10M | $4.91M | $4.45M | $4.90M | $3.82M | $4.94M | $5.03M | $4.97M | $-31.02M | $4.34M | $5.09M | $4.31M | $3.22M | $2.44M | $2.75M | $3.16M | $2.92M | $3.33M | $2.21M | $1.52M |
| Avg Forecast | $2.13M | $2.13M | $2.13M | $2.13M | $6.66M | $6.66M | $7.56M | $5.55M | $4.85M | $4.53M | $5.19M | $4.68M | $7.53M | $3.10M | $3.57M | $3.92M | $4.05M | $6.09M | $5.46M | $4.23M | $4.54M | $4.91M | $3.72M | $3.08M | $3.07M | $3.26M | $2.21M | $2.13M |
| High Forecast | $3.55M | $3.55M | $3.55M | $3.55M | $11.09M | $9.73M | $12.60M | $9.26M | $5.25M | $7.55M | $8.65M | $7.79M | $12.55M | $5.16M | $5.66M | $4.70M | $6.41M | $9.64M | $8.64M | $6.69M | $7.18M | $7.78M | $5.88M | $3.70M | $4.86M | $5.16M | $3.50M | $3.37M |
| Low Forecast | $676.16K | $676.16K | $676.16K | $676.16K | $2.11M | $3.59M | $2.40M | $1.76M | $4.44M | $1.44M | $1.65M | $1.48M | $2.39M | $983.14K | $1.46M | $3.13M | $1.65M | $2.49M | $2.23M | $1.73M | $1.85M | $2.01M | $1.52M | $2.47M | $1.25M | $1.33M | $903.58K | $869.52K |
| Surprise % | - | - | - | - | - | - | - | - | 0.64% | 1.08% | 0.86% | 1.05% | 0.51% | 1.59% | 1.41% | 1.27% | -7.66% | 0.71% | 0.93% | 1.02% | 0.71% | 0.50% | 0.74% | 1.02% | 0.95% | 1.02% | 1.00% | 0.71% |
HOOKIPA Pharma's average Quarter SG&A projection for Mar 24 is $5.55M, based on 1 Wall Street analysts, with a range of $1.76M to $9.26M. The forecast indicates a 79.41% rise compared to HOOK last annual SG&A of $3.10M (Dec 23).
HOOKIPA Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.25 | $-0.17 | $-0.22 | $-0.28 | $-0.23 | $-0.22 | $-0.23 | $-0.35 | $-0.65 | $-0.61 | $-0.52 | $-0.53 | $-0.46 | $-0.53 | $-0.28 | $-0.43 | $-0.40 | $-0.45 | $-0.63 | $-0.37 |
| Avg Forecast | $-2.00 | $-2.00 | $-1.90 | $-1.80 | $-1.42 | $-1.28 | $-1.25 | $-1.02 | $-2.81 | $-2.10 | $-2.08 | $-2.26 | $-2.07 | $-2.71 | $-3.60 | $-2.40 | $-5.69 | $-5.47 | $-5.20 | $-5.33 | $-5.62 | $-4.18 | $-4.60 | $-4.20 | $-4.65 | $-6.33 | $-5.10 | $-14.80 |
| High Forecast | $-0.23 | $-0.23 | $-0.21 | $-0.20 | $-0.16 | $-1.03 | $-0.14 | $-0.12 | $-2.02 | $-0.24 | $-0.23 | $-0.25 | $-0.23 | $-0.31 | $-0.83 | $-0.55 | $-1.31 | $-1.26 | $-1.20 | $-1.23 | $-1.30 | $-0.97 | $-1.06 | $-0.97 | $-1.07 | $-1.46 | $-1.18 | $-3.41 |
| Low Forecast | $-3.73 | $-3.73 | $-3.55 | $-3.36 | $-2.64 | $-1.53 | $-2.34 | $-1.91 | $-3.59 | $-3.92 | $-3.89 | $-4.22 | $-3.87 | $-5.07 | $-6.33 | $-4.22 | $-9.99 | $-9.61 | $-9.14 | $-9.37 | $-9.87 | $-7.35 | $-8.08 | $-7.38 | $-8.17 | $-11.11 | $-8.96 | $-26.01 |
| Surprise % | - | - | - | - | - | - | - | - | 0.09% | 0.08% | 0.11% | 0.12% | 0.11% | 0.08% | 0.06% | 0.15% | 0.11% | 0.11% | 0.10% | 0.10% | 0.08% | 0.13% | 0.06% | 0.10% | 0.09% | 0.07% | 0.12% | 0.02% |
According to undefined Wall Street analysts, HOOKIPA Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HOOK previous annual EPS of $NaN (undefined).
HOOKIPA Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
HOOK Forecast FAQ
Is HOOKIPA Pharma a good buy?
Yes, according to 4 Wall Street analysts, HOOKIPA Pharma (HOOK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of HOOK's total ratings.
What is HOOK's price target?
HOOKIPA Pharma (HOOK) average price target is $3 with a range of $3 to $3, implying a -39.88% from its last price of $4.99. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will HOOKIPA Pharma stock go up soon?
According to Wall Street analysts' prediction for HOOK stock, the company can go down by -39.88% (from the last price of $4.99 to the average price target of $3), down by -39.88% based on the highest stock price target, and down by -39.88% based on the lowest stock price target.
Can HOOKIPA Pharma stock reach $7?
HOOK's average twelve months analyst stock price target of $3 does not support the claim that HOOKIPA Pharma can reach $7 in the near future.
What are HOOKIPA Pharma's analysts' financial forecasts?
HOOKIPA Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $24.82M (high $40.08M, low $9.26M), average EBITDA is $-24.816M (high $-9.261M, low $-40.075M), average net income is $-62.349M (high $-18.138M, low $-106M), average SG&A $26.43M (high $42.68M, low $9.86M), and average EPS is $-4.973 (high $-1.447, low $-8.422). HOOK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $8M (high $13.33M, low $2.54M), average EBITDA is $-8M (high $-2.54M, low $-13.333M), average net income is $-96.549M (high $-10.881M, low $-180M), average SG&A $8.52M (high $14.2M, low $2.7M), and average EPS is $-7.7 (high $-0.868, low $-14.373).
Did the HOOK's actual financial results beat the analysts' financial forecasts?
Based on HOOKIPA Pharma's last annual report (Dec 2022), the company's revenue was $14.25M, which missed the average analysts forecast of $27.86M by -48.86%. Apple's EBITDA was $-73.155M, beating the average prediction of $-44.145M by 65.71%. The company's net income was $-65.145M, missing the average estimation of $-107M by -39.31%. Apple's SG&A was $18.76M, beating the average forecast of $18.12M by 3.55%. Lastly, the company's EPS was $-2.5, missing the average prediction of $-10.786 by -76.82%. In terms of the last quarterly report (Dec 2023), HOOKIPA Pharma's revenue was $7.41M, beating the average analysts' forecast of $4.55M by 62.79%. The company's EBITDA was $-16.851M, beating the average prediction of $-4.55M by 270.35%. HOOKIPA Pharma's net income was $-24.818M, missing the average estimation of $-35.2M by -29.49%. The company's SG&A was $3.1M, missing the average forecast of $4.85M by -36.11%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-2.807 by -91.09%